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Clinical Practice Guideline for Vitamin D 
 
 Guideline Decision Flow Diagram  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
∗Rule out malabsorptive causes of vitamin D deficiency such as celiac sprue, 
inflammatory bowel disease, and other malabsorptive disorders (Consider GI consult) 
∗∗If normal vitamin D levels (30-80 ng/ml) are not achieved despite following the 
above protocol, ensure that pharmaceutical grade vitamin D is being used. If normal 
vitamin D levels are not achieved despite the use of pharmaceutical grade vitamin D, 
obtain endocrinology consult 
Check 25-OH Vitamin D level at 
Annual Physical Examination 
< 20 ng/ml∗ 
(Deficient) 
 
20-29 ng/ml 
(Insufficient) 
30-80 ng/ml 
(Normal) 
Rx 50,000 IU of 
Vitamin D3 weekly 
for 8 weeks, then 
1,000 IU daily or 
50,000 IU monthly 
(assuming normal 
renal function) 
Recheck 25-OH 
Vitamin D level in 3 
months∗∗ 
Rx 50,000 IU of 
Vitamin D3 weekly 
for 4 weeks, then 
1,000 IU daily or 
50,000 IU monthly 
(assuming normal 
renal function) 
Recheck 25-OH 
Vitamin D level in 3 
months∗∗ 
Continue current 
regimen 
https://ntrs.nasa.gov/search.jsp?R=20130013531 2019-08-31T01:15:02+00:00Z
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Decision Flow Diagram Notes 
Vitamin D Levels will be determined initially at the time of the astronaut’s annual 
physical examination. Astronauts who will be flying operational missions prior to their 
next annual physical examination (or who will be flying a long duration mission in the 
next few years) should be evaluated and treated appropriately prior to their mission. The 
timing of this testing for these crewmembers will be left up to the discretion of the Crew 
Surgeon. The JSC Pharmacy has on formulary the 50,000 I.U. form of vitamin D3, which 
is authorized for active astronauts only. Other patients, including AOD, flight surgeons, 
family members, management astronauts and retired astronauts will need to purchase the 
vitamin D3 on their own, should they choose to take this supplement. Vitamin D2 may be 
substituted for vitamin D3. However, a recent study demonstrated that vitamin D2 
potency is less than one third that of vitamin D3.
1 
Level of Evidence for Recommendations 
Based on the literature reviewed regarding the skeletal consequences of vitamin D 
inadequacy, optimal vitamin D levels, vitamin D dosing, and vitamin D toxicity, there are 
sufficient randomized clinical trials supporting the efficacy and safety of the vitamin D 
recommendations made within this clinical practice guideline to consider the strength of 
evidence as Level A, Class I. 
Evidence Based Discussion 
   
Introduction 
 
          Vitamin D and its metabolites have clinical significance because they play a 
critical function in calcium homeostasis and bone metabolism.  Although not all of the 
pathologic mechanisms have been adequately described, vitamin D insufficiency and 
deficiency, as measured by low levels of 25-OH vitamin D, are associated with a variety 
of clinical conditions including osteoporosis, falls and fractures in the elderly, decreased 
immune function, bone pain, and possibly colon cancer and cardiovascular health.
2
 Apart 
from inadequate dietary intake, patients may present with low levels of vitamin D if they 
receive inadequate sunlight.   
 The astronaut population is potentially vulnerable to low levels of vitamin D for 
several reasons. Firstly, they may train for long periods in Star City, Russia, which by 
virtue of its northern latitude receives less sunlight in winter months. Secondly, 
astronauts are deprived of sunlight while aboard the International Space Station (ISS). In 
addition, ISS crew members are exposed to microgravity for prolonged durations and are 
likely to develop low bone mineral density despite the use of countermeasures. Therefore, 
closely monitoring and maintaining adequate vitamin D levels is important for the 
astronaut corps.   
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Vitamin D Physiology 
 
 Sunlight and ultraviolet light nonenzymatically photoisomerize provitamin D to 
vitamin D3 (cholecalciferol) in the skin, at which point cholecalciferol binds to vitamin D 
binding proteins (DBP) and is transported through the circulatory system to target organs 
for further metabolism and target organ activity.  Intestinal absorption is the other source 
of vitamin D.  Major dietary sources of vitamin D include fortified milk and other dairy 
products, fatty fish, cod liver oil and eggs.  In the United States milk is commonly 
fortified with vitamin D; in other countries, grain products are more commonly vitamin D 
fortified. 
 Dietary Vitamin D is packaged into micelles, absorbed by enterocytes, then 
further incorporated into chylomicrons.  As such, various pathologies associated with 
intestinal absorption may lead to low levels of vitamin D including, though not limited to: 
celiac disease, pancreatic insufficiency, cystic fibrosis, cholestatic liver disease, and 
inflammatory bowel disease (IBD).  Chylomicrons are brought to the liver via portal 
circulation, at which point vitamin D is hydroxylated by 25-vitamin D hydroxylase to 
form 25-hydroxy vitamin D.  Another hydroxylation reaction is accomplished within 
mitochondria located in proximal convoluted tubules of the kidney, which produces 1, 25 
dihydroxy vitamin D.
3
 This is the physiologically active form of vitamin D.  If a patient is 
noted to have low levels of vitamin D, the cause will therefore likely be found in 
inadequate sunlight exposure, inadequate intake or absorption, or inadequate 
hydroxylation of precursor molecules, either at the liver or at the kidney. Rare cases of 
end-target insensitivity to 1, 25 dihydroxy vitamin D have been described, but would be 
virtually impossible to witness within the astronaut corps. 
 Vitamin D absorption and hydroxylation to the physiologically active form are 
involved in calcium homeostasis and are linked to parathyroid hormone (PTH), serum 
calcium concentration, and phosphorous levels.
4
 When hypocalcemia occurs, serum PTH 
rises and acts to increase renal absorption of PTH and increased hydroxylation of 
Vitamin D to the active metabolite.  Increased 1, 25 dihydroxy vitamin D in turn 
promotes increased intestinal calcium absorption.
5
 PTH also induces bone osteoclasts to 
increase serum calcium from bone calcium stores.
 6
 
 Conversely, lack of vitamin D leads to reduced intestinal absorption of calcium 
and phosphorous.  Persistently low levels of vitamin D lead to a secondary 
hyperthyroidism that produces phosphaturia, demineralization of bones, and ultimately to 
osteomalacia in adults and rickets in children. 
 
Vitamin D Levels 
 
 Appropriate levels of vitamin D have been difficult to identify.  The main 
criterion defined has been the physiologic level needed to maximize PTH suppression. 
Studies of different populations of varying ethnicities and varying geographic areas have 
yielded varying levels of vitamin D.  Estimates of an acceptable lower level therefore 
vary but are approximately 30-32 ng/ml.
7-11
 It should be noted that 30 ng/mL is higher 
than most previously accepted lower ―normal‖ ranges, which suggests that these lower 
levels are perhaps set too low for adequate physiologic effect.  Higher 25-hydroxy 
vitamin D levels have been associated with greater calcium absorptive efficiency
12
 and 
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levels of 28 to 40 ng/ml may decrease bone fracture risk.
13,14
 In adults, vitamin D 
deficiency is defined as a serum 25-hydroxy vitamin D level of less than 20 ng/ml, and 
insufficiency is defined as a serum hydroxyl vitamin D level of 20 to 30 ng/ml.
15 
 
Vitamin D Toxicity 
 
 Vitamin D toxicity is infrequently witnessed, but hypercalcemia and 
hypercalciuria are among the first sequelae.  Accordingly, symptoms may include bone 
changes including pathologic fractures, polyuria, kidney stones, abdominal pain, 
anorexia, constipation, depression, and malaise.  Research has shown that these 
symptoms are only witnessed at levels of vitamin D higher than 88 ng/ml.
16,17
 Moreover; 
2000 IU/day (50 micrograms/day) has been set as the Safe Upper Limit by the National 
Academy of Sciences, as well as the ―tolerable upper intake level‖ by the Institute of 
Medicine.  However more recent research has indicated that even higher doses are safe at 
least over a several-month period.
18
  
  
RATING SCHEME FOR THE STRENGTH OF THE EVIDENCE 
Levels of Evidence 
A: Data derived from multiple randomized clinical trials or meta-analyses 
B: Data derived from a single randomized trial, or nonrandomized studies 
C: Only consensus opinion of experts, case studies, or standard-of-care 
Applying Classification of Recommendations and Level of Evidence 
  SIZE OF TREATMENT EFFECT 
  CLASS I  
 
Benefit >>> Risk  
 
Procedure/Treatment  
 
SHOULD be performed/ 
administered  
CLASS IIa  
 
Benefit >> Risk 
Additional studies with 
focused objectives needed  
 
IT IS REASONABLE to 
perform 
procedure/administer 
treatment  
CLASS IIb  
 
Benefit > Risk 
Additional studies with 
broad objectives needed; 
additional registry data 
would be helpful  
 
Procedure/Treatment 
MAY BE CONSIDERED  
CLASS III  
 
Risk > Benefit 
No additional studies needed  
 
Procedure/Treatment should 
NOT be 
performed/administered 
SINCE IT IS NOT 
HELPFUL AND MAY BE 
HARMFUL  
Estimate of 
Certainty 
(Precision) of 
Treatment Effect 
LEVEL A  
 
Multiple (3–
5) 
population 
risk strata 
evaluated*  
 
General 
consistency 
of direction 
and 
 Recommendation that 
procedure or treatment 
is useful/effective 
 Sufficient evidence 
from multiple 
randomized trials or 
meta-analyses 
 Recommendation in 
favor of treatment of 
procedure being 
useful/effective 
 Some conflicting 
evidence from 
multiple randomized 
trials or meta-analyses 
 Recommendation's 
usefulness/efficacy 
less well established 
 Greater conflicting 
evidence from 
multiple randomized 
trials or meta-analyses 
 Recommendation that 
procedure or treatment 
is not useful/effective 
and may be harmful 
 Sufficient evidence 
from multiple 
randomized trials or 
meta-analyses 
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  SIZE OF TREATMENT EFFECT 
magnitude of 
effect  
LEVEL B  
 
Limited (2–
3) 
population 
risk strata 
evaluated*  
 Recommendation that 
procedure or treatment 
is useful/effective 
 Limited evidence from 
single randomized trial 
or nonrandomized 
studies 
 Recommendation in 
favor of treatment of 
procedure being 
useful/effective 
 Some conflicting 
evidence from single 
randomized trial or 
nonrandomized studies 
 Recommendation's 
usefulness/efficacy 
less well established 
 Greater conflicting 
evidence from single 
randomized trial or 
nonrandomized studies 
 Recommendation that 
procedure or treatment 
is not useful/effective 
and may be harmful 
 Limited evidence from 
single randomized trial 
or nonrandomized 
studies 
LEVEL C  
 
Very limited 
(1–2) 
population 
risk strata 
evaluated*  
 Recommendation that 
procedure or treatment 
is useful/effective 
 Only expert opinion, 
case studies, or 
standard-of-care 
 Recommendation in 
favor of treatment of 
procedure being 
useful/effective 
 Only diverging expert 
opinion, case studies, 
or standard-of-care 
 Recommendation's 
usefulness/efficacy 
less well established 
 Only diverging expert 
opinion, case studies, 
or standard-of-care 
 Recommendation that 
procedure or treatment 
is not useful/effective 
and may be harmful 
 Only expert opinion, 
case studies, or 
standard-of-care 
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This Guideline is to be reviewed no less than every 2 years.  
